Hemostemix Inc. (CVE:HEM – Get Rating) stock price fell 15.8% during Thursday’s trading. The stock traded as low as C$0.21 and last traded at C$0.24. About 243,887 shares changed hands during the midday session, a 138% increase from the average daily volume of 102,354 shares. The stock had previously closed at C$0.29.
The company has a market cap of C$17.75 million and a price-to-earnings ratio of -2.11. The company has a 50-day moving average price of CA$0.31 and a 200-day moving average price of CA$0.23.
Separately, director Thomas Smeenk sold 300,000 shares of the company in a transaction on Monday, April 18. The stock was sold at an average price of CA$0.31, for a total value of CA$93,210.00. Following the completion of the sale, the administrator now owns 1,149,125 shares of the company, valued at C$357,033.14.
About Hemostemix (CVE:HEM)
Hemostemix Inc, a biotechnology company, develops, manufactures and markets blood-derived stem cell therapies for medical conditions. The Company develops cell therapy products from the patient’s own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in a phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of cardiac and peripheral arterial diseases. .
Get news and reviews for Hemostemix Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Hemostemix and related companies with MarketBeat.com’s FREE daily newsletter.